Exosome-targeted DNA vaccine
AssigneeExorphia, Inc.
InventorsKen Ishii, Kouji Kobiyama, Tomohiro Kanuma
Life of this patent
Estimating the term…
Abstract
In order to further increase antigenicity to provide a DNA vaccine which is clinically usable in humans, the inventors of the present invention focused on exosomes, which are garnering attention as tools for DDS, and discovered that an exosome expressing a fusion antigen of an exosome (extracellular microparticle)-constituent protein and a vaccine antigen has excellent cytotoxic T-cell inducibility. Consequently, the present invention provides a nucleic acid constituent including a nucleic acid sequence coding for an exosome marker protein and a nucleic acid sequence coding for a vaccine antigen.
Claims11
A method of enhancing an immune response in a subject, comprising administering to the subject an effective amount of a composition that comprises at least one selected from the group of:
- (a) a nucleic acid construct comprising a first nucleic acid sequence encoding an exosome marker protein and a second nucleic acid sequence encoding a vaccine antigen, wherein the exosome marker protein and the vaccine antigen are expressed in a fused form;
- (b) a protein in a form of a vaccine antigen protein fused with an exosome marker protein so that the fused protein is present in an exosome;
- and (c) an exosome comprising a vaccine antigen protein and an exosome marker protein in a fused form, wherein the exosome is an extracellular membrane vesicle.
Dependencies are inferred from the claim text.